PYC Therapeutics Limited (ASX: PYC) insider raised 0.06% stake earlier this year


Insiders were net buyers of PYC Therapeutics Limited (ASX: PYC ) stock during the past year. That is, insiders bought more shares than they sold.

While we never suggest that investors should base their decisions solely on what a company’s directors have done, we would consider it foolish to ignore insider trading altogether.

Check out our latest review for PYC Therapeutics

PYC Therapeutics Insider Trading in the Past Year

In fact, the recent sale by Bernard Hockings was the biggest sale of PYC Therapeutics shares by an insider in the past twelve months, according to our records. While we generally don’t like to see insider sales, it is more of a concern whether the sales come at a lower price. It is heartwarming that this sale was made at a much higher price than the current share price, which is AU $ 0.14. So it might not shed much light on insider confidence at current levels.

Below you can see a visual representation of insider trading (by businesses and individuals) over the past 12 months. If you want to know exactly who sold, for how much and when, just click on the graph below!


If you are like me then you not want to miss it free list of growing companies that insiders buy.

PYC Therapeutics insiders sell their shares

Over the past three months, we’ve seen significant insider sales at PYC Therapeutics. In total, insider Bernard Hockings sold AUS $ 10 million worth of shares during this period, and we did not record any purchases. This may suggest that some insiders think stocks aren’t cheap.

Does PYC Therapeutics boast strong insider ownership?

Another way to test the alignment between a company’s executives and other shareholders is to look at how many shares they own. I think it’s a good sign if the insiders own a significant number of shares in the company. PYC Therapeutics insiders own around A $ 218 million in shares (or 51% of the company). This type of large insider ownership generally increases the chances that the business will be run in the best interests of all shareholders.

So what do PYC Therapeutics’ insider trading indicate?

An insider recently sold stocks, but they didn’t buy. With zooming out, the longer term image doesn’t give us much comfort. Although insiders own many shares of the company (which is good), our analysis of their transactions does not give us confidence in the company. In addition to knowing the current insider transactions, it is useful to identify the risks that PYC Therapeutics faces. To help you, we have discovered 2 warning signs (1 is a concern!) That you should know before buying shares of PYC Therapeutics.

Sure, you might find a fantastic investment looking elsewhere. So take a look at this free list of interesting companies.

For the purposes of this article, insiders are those persons who report their transactions to the relevant regulatory body. We currently account for open market transactions and private assignments, but not derivative transactions.

Do you have any feedback on this item? Are you worried about the content? Get in touch with us directly. You can also send an email to the editorial team (at)

This Simply Wall St article is general in nature. We provide commentary based on historical data and analyst forecasts using only unbiased methodology and our articles are not intended to be financial advice. It does not constitute a recommendation to buy or sell any stock and does not take into account your goals or your financial situation. Our aim is to bring you long-term, targeted analysis based on fundamental data. Note that our analysis may not take into account the latest announcements from price sensitive companies or qualitative documents. Simply Wall St has no position in any of the stocks mentioned.

Source link


About Author

Comments are closed.